Bloom Energy, Gold.com Lead 5 Stocks Up 15-19% on EPS Revisions
Bloom Energy surged 16.8% to $275.11 after S&P 500 inclusion news reinforced an EPS estimate upgrade, while Gold.com climbed 17.0% to $48.55 on strong Q4 results and an estimate bump. Montauk Renewables, Amber International and PMV Pharmaceuticals each rose over 15% following upward EPS revisions detected by our screener.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| MNTK | Basic Materials | 2026-09-04 | +5.3pp | +18.8% |
| AMBR | Financial | 2026-09-04 | N/A | +18.7% |
| GOLD | Financial | 2026-09-03 | +2.4pp | +17.0% |
| BE | Industrials | 2026-09-03 | +1.7pp | +16.8% |
| PMVP | Healthcare | 2026-09-04 | N/A | +15.5% |
Why did MNTK stock jump in September 2026?
MNTK jumped 18.8% (from $2.23 to $2.65) after its next-year EPS growth estimate was revised upward to 40.6% on September 4, 2026.
The renewable natural gas producer benefited from sector-wide tailwinds as investors rotated into clean energy infrastructure names with improving profitability visibility. With no company-specific news in the window, the move reflects broader enthusiasm for Basic Materials stocks with accelerating earnings trajectories. The screener detected the positive revision early, and the market confirmed it through sustained buying pressure over the following week.
MNTK EPS revision history → · Screener snapshot from 2026-09-04 →
FAQ: MNTK
Why did MNTK stock jump?
MNTK jumped 18.8% to $2.65 after its next-year EPS growth estimate was revised to 40.6% on September 4, 2026, driven by sector rotation into renewable energy names.
What is MNTK's EPS growth estimate?
MNTK's next-year EPS growth estimate stands at 40.6%, up from the previous 35.3% as of the September 4 revision.
Is MNTK a buy after the rally?
The stock's 18.8% gain reflects improving earnings estimates and sector momentum, though investors should weigh the limited company-specific news against the broader clean energy tailwinds.
Why did AMBR stock jump in September 2026?
AMBR surged 18.7% (from $0.91 to $1.08) after a Q2 2026 earnings call on September 3 highlighted 38.8% sequential revenue growth and positive operating income.
The company reported revenue of $13.9 million, gross margin expansion to 79.5%, and net income of $1.5 million—marking a sharp turnaround from a $3.7 million net loss in Q1. Amber International is executing a strategic pivot to specialized AI agents, with its AMM platform contributing $3.5 million in its first quarter of revenue recognition. The improved profitability, coupled with the 200% EPS growth estimate, triggered the upward estimate revision that preceded the price gain.
AMBR EPS revision history → · Screener snapshot from 2026-09-04 →
FAQ: AMBR
Why did AMBR stock surge?
AMBR jumped 18.7% after its September 3 Q2 2026 earnings call revealed 38.8% revenue growth to $13.9 million and a swing to positive net income, reinforcing a 200% EPS growth estimate.
Is AMBR a buy after the rally?
The company's pivot to AI agents and Q2 profitability turned positive with operating income of $1 million, but the 18.7% surge already prices in near-term optimism.
What caused AMBR's Q2 profitability turnaround?
AMBR achieved net income of $1.5 million in Q2 2026 by expanding gross margins to 79.5% and driving operating leverage with flat expenses at $10 million.
Why did GOLD stock jump in September 2026?
GOLD climbed 17.0% (from $41.48 to $48.55) after a September 3 earnings report showed fiscal Q4 revenue nearly doubling to $5.01 billion and adjusted EPS of 83 cents.
The precious metals trader also benefited from an upward revision to its next-year EPS growth estimate, now at 31.6%, as the company integrated acquisitions and expanded its vertically integrated model. Gold.com sold 521,000 ounces in Q4, up 51% year-over-year, and ended with $578 million in cash. Despite a retail demand slowdown from precious metal price retreats, wholesale and institutional segments remained resilient, providing the earnings foundation for the estimate upgrade.
GOLD EPS revision history → · Screener snapshot from 2026-09-03 →
FAQ: GOLD
Why did GOLD stock jump?
GOLD jumped 17% to $48.55 after its September 3 fiscal Q4 report showed revenue nearly doubling to $5.01 billion and adjusted EPS of 83 cents, prompting an upward EPS estimate revision to 31.6%.
What is GOLD's EPS growth estimate?
GOLD's next-year EPS growth estimate was revised upward to 31.6%, reflecting the company's strong Q4 results and acquisition-driven revenue growth.
Is GOLD a buy after the rally?
The strong revenue and earnings beat, along with $578 million in cash, supports the bull case, though retail demand has softened from peak levels.
Why did BE stock jump in September 2026?
BE soared 16.8% (from $235.55 to $275.11) after its next-year EPS growth estimate was revised to 84.1% on September 3, followed by confirmation from S&P 500 inclusion news on September 7.
Bloom Energy's addition to the S&P 500 on September 21 triggered passive fund buying, with UBS raising its price target to $325 and noting historical increases in passive ownership for new index constituents. As the first energy stock to join the index since 2022, BE attracted heightened investor attention. The combination of a strong earnings revision and index inclusion created a powerful catalyst for the stock's sustained rally.
BE EPS revision history → · Screener snapshot from 2026-09-03 →
FAQ: BE
Why did BE stock jump?
BE jumped 16.8% to $275.11 after its EPS growth estimate was revised to 84.1% on September 3 and S&P 500 inclusion was announced on September 7, driving passive fund demand.
What is BE's EPS growth estimate?
BE's next-year EPS growth estimate is 84.1%, revised upward from 82.4%, reflecting the company's improving earnings outlook.
Is BE a buy after the S&P 500 inclusion rally?
UBS raised its target to $325 with a Buy rating, implying over 28% upside from recent levels, though the stock has already rallied significantly on index inclusion.
Why did PMVP stock jump in September 2026?
PMVP gained 15.5% (from $1.29 to $1.49) after its next-year EPS growth estimate was set at 25.1% on September 4, 2026.
The clinical-stage biopharmaceutical company focuses on p53-targeted cancer therapies, and the positive estimate revision suggests improving analyst confidence in its pipeline. With no company-specific earnings news in the window, the stock's move aligns with broader strength in small-cap healthcare names. The screener captured the upward revision early, and the subsequent price action reflects growing investor interest in the company's development programs.
PMVP EPS revision history → · Screener snapshot from 2026-09-04 →
FAQ: PMVP
Why did PMVP stock jump?
PMVP rose 15.5% to $1.49 after its next-year EPS growth estimate was revised to 25.1% on September 4, 2026, reflecting improving analyst sentiment on its cancer therapy pipeline.
What is PMVP's EPS growth estimate?
PMVP's next-year EPS growth estimate is 25.1%, indicating expectations for narrowing losses as its clinical programs advance.
Is PMVP a buy after the recent rally?
The stock's 15.5% gain on positive estimate revisions suggests growing confidence, but as a clinical-stage biotech, its prospects remain tied to trial outcomes.
Today's top performers reflect a market rewarding companies with upward EPS revisions, particularly those in renewable energy, precious metals, and AI-driven financial services. The combination of estimate upgrades and strategic catalysts like S&P 500 inclusion underscores the momentum behind earnings-driven stock selection in the current environment.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →